Clinical trials: Supratentorial Neoplasms, Malignant
Acromegaly, Pituitary Neoplasm
The Treatment and Natural History of Acromegaly
The purpose of this study is to investigate the treatment and natural history of acromegaly. We have a longstanding interest in acromegaly treatment, and a cohort that has been followed for 30 years, or more in some cases.
- Trial name
- NCT00001981
- Where
- United States
- Volunteers
- 117 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Pituitary Disease
China Pituitary Disease Registry (CAPASITY)
Epidemiologic studies have revealed a tremendous increase in the prevalence of pituitary disease and related mortality worldwide.
- Trial name
- NCT04713293
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Pituitary Tumor, Pituitary Adenoma
Detection of PitNET Tissue During TSS Using Bevacizumab-800CW
There is a need for improved visualization of presence and extent of pituitary neuroendocrine tumor (PitNET) tissue during transsphenoidal surgery (TSS), especially in tumors invading the cavernous sinus (CS).
- Conditions
- Pituitary Tumor, Pituitary Adenoma, Pituitary Macroadenoma
- Trial name
- DEPARTURE (NCT04212793)
- Testing
- Bevacizumab-IRDye800CW, Molecular Fluorescence Endoscopy platform
- Where
- Netherlands
- Volunteers
- 20 people
- Sponsor
- University Medical Center Groningen
Glioblastoma (GBM)
A Phase 1b/2a Study to Evaluate the Safety, Pharmacokinetics, and Objective Response of STAR-001 (LP-184) in Combination With Spironolactone in Supratentorial Glioblastoma at First Progression
Approximately 58-68 total subjects will be enrolled. In the first stage, 10 response evaluable subjects (either IDHwt or IDHm Grade 4 astrocytoma) will be enrolled.
- Trial name
- NCT07431216
- Testing
- STAR-001 (LP-184) will be administered via IV infusion over 30 (± 5) minutes on Day 1 and Day 8 of each 21-day cycle., Spironolactone (drug)
- Volunteers
- 68 people
- Sponsor
- Starlight Therapeutics Inc.
Malignant Glioma, Ependymoma
Optune for Children With High-Grade Glioma or Ependymoma, and Optune With Radiation Therapy for Children With DIPG
This is a multicenter trial of the Optune device to examine the feasibility and to describe the device-related toxicity in children with supratentorial high grade glioma (HGG) or ependymoma (Stratum 1) and to examine the…
- Conditions
- Malignant Glioma, Ependymoma, Diffuse Intrinsic Pontine Glioma
- Trial name
- NCT03033992
- Testing
- Optune System (NovoTTF-200A System, Tumor Treating Fields, TTFields), Concurrent Optune and RT followed by Optune System alone
- Where
- 11 sites in United States
- Volunteers
- 80 people
- Sponsor
- Children's Oncology Group
Childhood Acute Promyelocytic Leukemia (M3), Childhood Atypical Teratoid/Rhabdoid Tumor
Vorinostat With or Without Isotretinoin in Treating Young Patients With Recurrent or Refractory Solid Tumors, Lymphoma, or Leukemia
This phase I trial is studying the side effects and best dose of vorinostat when given together with isotretinoin in treating young patients with recurrent or refractory solid tumors, lymphoma, or leukemia.
- Conditions
- Childhood Acute Promyelocytic Leukemia (M3), Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Burkitt Lymphoma, Childhood Chronic Myelogenous Leukemia
- Trial name
- NCT00217412
- Testing
- vorinostat, isotretinoin
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Brain and Central Nervous System Tumors
Pyrazoloacridine Followed by Radiation Therapy in Treating Adults With Newly Diagnosed Supratentorial Glioblastoma Multiforme
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00006355
- Testing
- pyrazoloacridine, adjuvant therapy, radiation therapy
- Where
- 8 sites in United States
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Supratentorial Neoplasms, Brain Tumor, Primary
Comparison of Stroke Volume Variation-guided Normovolemic and Restrictive Fluid Management During Craniotomy: a Randomized Controlled Trial
Fluid management during neurosurgery presents a special clinical agenda. Volume overload can have detrimental effects on intracranial pressure by increasing either cerebral blood volume or hydrostatically driven cerebral edema…
- Conditions
- Supratentorial Neoplasms, Brain Tumor, Primary, Craniotomy
- Trial name
- NCT02113358
- Testing
- Intravenous colloid bolus with Voluven
- Where
- Taiwan
- Volunteers
- 80 people
- Sponsor
- National Taiwan University Hospital
Pituitary Diseases, Pituitary Neoplasms
Long Term Outcome Study in Patients With Pituitary Disorders
To determine the outcomes of patients with different pituitary disorders whether they are managed medically, surgically or expectantly.
- Trial name
- NCT03665064
- Volunteers
- 1,500 people
- Sponsor
- University of Alberta
Adult Giant Cell Glioblastoma, Adult Glioblastoma
Motexafin Gadolinium, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
This phase I/II trial is studying the side effects and best dose of motexafin gadolinium when given together with temozolomide and radiation therapy and to see how well they work in treating patients with newly diagnosed…
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma
- Trial name
- NCT00305864
- Testing
- 3-Dimensional Conformal Radiation Therapy, Motexafin Gadolinium, Temozolomide
- Where
- 106 sites in United States
- Volunteers
- 118 people
- Sponsor
- National Cancer Institute (NCI)
Malformations, Multiple Abnormalies
Phenotype and Etiology of Pallister-Hall Syndrome
We aim to delineate the range of severity, natural history, molecular etiology, and pathophysiology of Pallister-Hall syndrome (PHS), Greig cephalopolysyndactyly syndrome (GCPS), McKusick-Kaufman syndrome (MKS), Bardet-Biedl…
- Conditions
- Malformations, Multiple Abnormalies, Polydactyly
- Trial name
- NCT00001404
- Where
- 4 sites in United States, Turkey (Türkiye)
- Volunteers
- 1,170 people
- Sponsor
- National Human Genome Research Institute (NHGRI)
Pituitary Adenoma
Use of [18F] Fluoroethyl-L-tyrosine PET/MRI for Identifying Small Functional Pituitary Adenomas
The purpose of this research is to evaluate the diagnostic role and clinical efficacy of investigational FET-PET/MRI in detecting MRI-occult primary or residual/recurrent functional pituitary adenomas (PAs) and its influence on…
- Trial name
- NCT07456878
- Testing
- FET-PET/MRI
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Mayo Clinic
Acromegaly
Pasireotide in Patients With Acromegaly Inadequately Controlled With First Generation Somatostatin Analogues
This is a phase IIIb multicenter, open-label; single arm study to evaluate the efficacy and safety of pasireotide LAR 40 mg and 60 mg in patients with inadequately controlled acromegaly with maximal approved doses of first…
- Trial name
- NCT02354508
- Testing
- Pasireotide LAR
- Where
- 50 sites in Argentina, Belgium and 13 more
- Volunteers
- 123 people
- Sponsor
- Novartis Pharmaceuticals
Pleuropulmonary Blastoma, Cystic Nephroma
Elucidating the Genetic Basis of the Pleuropulmonary Blastoma (PPB) Familial Cancer Syndrome
Pleuropulmonary Blastoma (PPB) is a rare lung tumor which develops in childhood. The underlying genetic factors which contribute to the development and progression of PPB are not defined.
- Conditions
- Pleuropulmonary Blastoma, Cystic Nephroma, Sertoli-Leydig Cell Tumor of Ovary, Medulloepithelioma
- Trial name
- PPB (NCT00565903)
- Where
- United States
- Volunteers
- 1,247 people, healthy volunteers welcome
- Sponsor
- Ashley Hill
Glioblastoma Multiforme
The PRECISE Trial: Study of IL13-PE38QQR Compared to GLIADEL Wafer in Patients With Recurrent Glioblastoma Multiforme
The purpose of the PRECISE trial is to determine whether overall survival duration, safety, and quality of life are improved for patients treated with IL13-PE38QQR compared to patients treated with GLIADEL® Wafer following…
- Trial name
- NCT00076986
- Testing
- IL13-PE38QQR, surgery and catheter placement (2 procedures), prolifespan 20 with carmustine implant (GLIADEL® Wafer)
- Where
- 60 sites in United States, Canada and 4 more
- Volunteers
- 300 people
- Sponsor
- INSYS Therapeutics Inc
Brain and Central Nervous System Tumors
Combination Chemotherapy With or Without Etoposide Followed By an Autologous Stem Cell Transplant in Treating Young Patients With Previously Untreated Malignant Brain Tumors
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00392886
- Testing
- carboplatin, cisplatin, cyclophosphamide
- Where
- 37 sites in United States, Australia and 3 more
- Volunteers
- 120 people
- Sponsor
- Children's Hospital Los Angeles
Prolactinoma, Prolactin-Producing Pituitary Tumor
Validation of a Quality of Life Metric "Prolac-10"
This is a short-term validation study of a quality of life metric "Prolac-10" for patients diagnosed with a prolactinoma, undergoing new medical therapy.
- Conditions
- Prolactinoma, Prolactin-Producing Pituitary Tumor, Pituitary Tumor, Prolactinoma Macroadenoma
- Trial name
- Prolac-10 (NCT04106531)
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Ohio State University
Brain and Central Nervous System Tumors
Radiation Therapy and Combination Chemotherapy in Treating Young Patients With Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Ependymoma
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00303810
- Testing
- carboplatin, cisplatin, cyclophosphamide
- Where
- Germany
- Volunteers
- 567 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf